Comparing Scinai Immunotherapeutics (NASDAQ:SCNI) and Oncolytics Biotech (NASDAQ:ONCY)

Scinai Immunotherapeutics (NASDAQ:SCNI) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Profitability

This table compares Scinai Immunotherapeutics and Oncolytics Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Risk and Volatility

Scinai Immunotherapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Institutional and Insider Ownership

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Scinai Immunotherapeutics and Oncolytics Biotech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31 million	0.88	-$8.31 million	($4.63)	-0.06
Oncolytics Biotech	N/A	N/A	-$28.76 million	($0.31)	-2.96

Scinai Immunotherapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Scinai Immunotherapeutics and Oncolytics Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Oncolytics Biotech	1	0	2	1	2.75

Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 826.73%. Given Oncolytics Biotech’s stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Scinai Immunotherapeutics.

Summary

Scinai Immunotherapeutics beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.